Drugs / Tagitanlimab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT07701681 | Aug 2026 → Sep 2028 expected | esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07492914 | May → Dec 2026 expected | head and neck squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07179783 | Sep 2025 → Jun 2027 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma, prostate neuroendocrine neoplasm | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07153965 | Sep 2025 → Sep 2026 overdue | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07109284 | Sep 2025 → Jan 2028 expected | estrogen-receptor positive breast cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07108816 | Aug 2025 → Dec 2026 expected | — | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05367635 Background | Mar 2022 → Jun 2026 overdue | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC kelun-biotech.com ↗ |
| 2025-01-21 | Klus Pharma Inc. | Kelun-Biotech’s Product Tagitanlimab Approved for Marketing for Second Indication in China kluspharma.com ↗ |
| 2025-01-21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech’s Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC kelun-biotech.com ↗ |
| 2024-12-31 | Klus Pharma Inc. | Kelun-Biotech's Anti-PD-L1 (Tagitanlimab) Receives NMPA Approval for Marketing kluspharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tagitanlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179783 ↗ |
| Known as | KL-A167 | “Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167)” NCT07701681 ↗ |
| Action | Inhibit | “blocks the PD-1/PD-L1 signaling pathway” NCT07492914 ↗ |
| Modality | Monoclonal antibody | “Humanized IgG1κ anti-PD-L1 monoclonal antibody” NCT07492914 ↗ |
| Route | Intravenous | “Tagitanlimab 900mg IV every 2 weeks on Day 1” NCT07153965 ↗ |
| Target | CD274 | “Humanized IgG1κ anti-PD-L1 monoclonal antibody” NCT07492914 ↗ |